Zepbound Cost in Colorado: Pricing, Insurance, and Savings in 2026

What Does Zepbound Actually Cost in Colorado?

The short answer: $1,059 per month at list price, regardless of dose. That figure comes directly from Eli Lilly's published wholesale acquisition cost and holds steady across Colorado retail pharmacies in 2026. Patients without insurance or discount programs will pay this amount out of pocket.

Zepbound (tirzepatide) received FDA approval for chronic weight management in November 2023 based on the SURMOUNT clinical trial program. The drug is a dual GIP/GLP-1 receptor agonist administered as a once-weekly subcutaneous injection, with doses titrated from 2.5 mg up to a maximum of 15 mg. Unlike some weight-loss medications where pricing varies by dose strength, Eli Lilly uses a flat pricing model. Every single-dose pen costs the same whether it contains 2.5 mg or 15 mg.

Colorado follows national pricing trends closely. A survey of major Colorado retail chains (Walgreens, King Soopers, Safeway, CVS) shows cash-pay prices clustering within a few dollars of that $1,059 mark. Some independent pharmacies may offer marginally lower pricing through wholesale purchasing arrangements, but savings rarely exceed $30 to $50 per fill.

The annual cost without any assistance: $12,708. That figure prices out a significant portion of Colorado residents, which is why understanding insurance pathways and discount programs matters as much as knowing the sticker price.

Does Colorado Medicaid Cover Zepbound?

No. Colorado Medicaid (Health First Colorado) does not cover Zepbound for chronic weight management as of 2026. The program does cover tirzepatide under the brand name Mounjaro for type 2 diabetes management, but the weight-management indication remains excluded from the preferred drug list.

This exclusion follows a pattern seen across most state Medicaid programs nationwide. The Centers for Medicare and Medicaid Services allows states to exclude weight-loss drugs from Medicaid formularies under Section 1927(d)(2) of the Social Security Act, and Colorado has exercised that option. The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times but has not yet passed into law.

For Colorado Medicaid enrollees who also have type 2 diabetes, there is a pathway. Mounjaro (the same tirzepatide molecule) may be covered when prescribed specifically for glycemic control. The prescriber must document the T2D diagnosis and show that the patient meets clinical criteria. Prior authorization is typically required, and the prescriber should be prepared to document failure of or contraindication to metformin.

Colorado's Department of Health Care Policy and Financing reviews its preferred drug list quarterly. Patients and advocates can track updates through the Colorado Drug Utilization Review Board meeting schedule and public comment periods.

Which Colorado Insurance Plans Cover Zepbound?

Commercial insurance coverage for Zepbound in Colorado is inconsistent and plan-specific. Large employer-sponsored plans from carriers like Anthem Blue Cross Blue Shield, UnitedHealthcare, Cigna, and Aetna have begun adding Zepbound to formularies, but coverage often requires prior authorization and step therapy.

Prior authorization criteria typically include a documented BMI of 30 or greater (or 27 or greater with at least one weight-related comorbidity such as hypertension, dyslipidemia, or obstructive sleep apnea), failure of lifestyle interventions for at least 6 months, and in some cases failure of a first-line GLP-1 receptor agonist like semaglutide. The SURMOUNT-1 trial (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks versus 2.4% for placebo, data that payers increasingly recognize as cost-effective when weighed against downstream comorbidity costs.

Colorado's Division of Insurance does not mandate coverage for anti-obesity medications in state-regulated individual and small-group plans. Self-insured employer plans (governed by ERISA, not state law) set their own formulary rules entirely.

To check your specific plan: call the number on the back of your insurance card and ask whether Zepbound (NDC 00002-1506-80 for the starter dose) carries formulary coverage. Request the prior authorization criteria in writing so your prescriber can submit a complete request on the first attempt.

How the Eli Lilly Savings Card Works in Colorado

Eli Lilly offers the Zepbound Savings Card program for commercially insured patients in Colorado. The program can reduce monthly out-of-pocket costs to as little as $25 per fill for eligible patients.

Eligibility requirements are straightforward. You must have commercial insurance (not Medicare, Medicaid, or Tricare), a valid Zepbound prescription, and you cannot be enrolled in any state or federal healthcare program. The savings card applies at the pharmacy point of sale and covers the difference between your insurance copay and $25, up to a maximum benefit of $150 per fill or $1,800 per calendar year.

For commercially insured patients whose plans cover Zepbound but impose a high copay, this card is the single most effective cost-reduction tool available. A patient with a $200 monthly copay would pay $25 and the card would cover the remaining $175.

For patients whose commercial insurance does not cover Zepbound at all, Lilly offers a separate cash-pay savings program. Under this arrangement, patients pay approximately $550 per month out of pocket, a 48% reduction from the $1,059 list price. This program also excludes government-insured patients.

Both programs require enrollment through the Lilly website or by calling Lilly's customer support line. Activation takes 24 to 48 hours, and the card is presented at the pharmacy as a secondary payer.

Compounded Tirzepatide in Colorado: Legality, Cost, and Risks

Compounded tirzepatide is available in Colorado through licensed 503A compounding pharmacies at an average price of approximately $249 per month. That represents a 76% savings over the brand-name list price.

The legal framework: under Section 503A of the Federal Food, Drug, and Cosmetic Act, a compounding pharmacy may prepare a compounded version of a commercially available drug when it holds a valid prescription for an individual patient and operates under state board of pharmacy oversight. The Colorado State Board of Pharmacy licenses and inspects 503A pharmacies operating within the state. Tirzepatide appeared on the FDA drug shortage list for an extended period, which expanded compounding access. As of 2026, compounding eligibility depends on current shortage status and individual clinical justification.

The cost difference is significant. However, compounded tirzepatide is not FDA-approved Zepbound. The SURMOUNT-1 and SURMOUNT-2 trials tested the branded product manufactured under Lilly's cGMP process. Compounded versions may differ in purity, potency, sterility, and stability. The FDA has issued warnings about adverse events associated with compounded semaglutide and tirzepatide products, including reports of dosing errors and sterility failures.

"Compounded GLP-1 receptor agonists lack the rigorous quality controls of FDA-approved products, and patients should understand the potential risks before choosing this route," stated the Endocrine Society in its 2023 clinical practice guideline on pharmacological management of obesity.

Patients considering compounded tirzepatide in Colorado should verify the pharmacy holds a valid Colorado Board of Pharmacy license, ask for a certificate of analysis for the specific batch, confirm the pharmacy uses a third-party potency and sterility testing lab, and discuss the decision with their prescribing provider.

Getting Zepbound via Telehealth in Colorado

Colorado permits telehealth prescribing of Zepbound. Patients can obtain prescriptions from both in-state and out-of-state providers licensed in Colorado without an in-person visit. The Colorado Medical Board allows prescribers to establish a patient-provider relationship via synchronous audio-video telemedicine, which means a video visit satisfies the requirement.

Multiple telehealth platforms operate in Colorado and prescribe Zepbound, including HealthRX, Ro, Hims, Found, and Calibrate. Pricing structures vary. Some platforms charge a monthly membership fee ($50 to $150) on top of medication costs, while others bundle the consultation fee into the medication price.

For Colorado patients in rural areas or those without convenient access to obesity medicine specialists, telehealth removes a major barrier. A 2024 analysis published in JAMA Network Open found that telehealth-initiated GLP-1 prescriptions showed comparable 12-month weight-loss outcomes to in-person-initiated prescriptions when paired with regular follow-up.

When evaluating a telehealth provider for Zepbound in Colorado, confirm the prescriber holds an active Colorado medical license, ask whether the platform handles prior authorization with your insurance, and verify whether they prescribe brand Zepbound, compounded tirzepatide, or both.

How Zepbound Pricing Compares to Alternatives in Colorado

Zepbound is not the only option. Understanding relative pricing helps Colorado patients make informed decisions with their prescribers.

Wegovy (semaglutide 2.4 mg) lists at approximately $1,349 per month, making it nearly $300 per month more expensive than Zepbound at list price. Both are once-weekly injectables approved for chronic weight management. The SURMOUNT-1 trial showed tirzepatide 15 mg achieved 22.5% weight loss at 72 weeks, while the STEP-1 trial (N=1,961) showed semaglutide 2.4 mg achieved 14.9% at 68 weeks. Direct head-to-head data from the SURMOUNT-5 trial have confirmed tirzepatide's superiority over semaglutide for weight reduction.

Oral semaglutide (Rybelsus, approved for T2D) and the higher-dose oral semaglutide (approved for weight management in some markets) offer a non-injectable alternative but are not approved for the same indication in all cases.

Contrave (naltrexone-bupropion) costs approximately $100 to $300 per month and is available as a generic. Weight loss is more modest, typically 5% to 8% of body weight. Phentermine, available generically, costs $15 to $50 per month but is approved only for short-term use (12 weeks).

"For patients with a BMI of 30 or above, tirzepatide and semaglutide represent the most effective pharmacotherapy options currently available, with weight reductions that approach those seen with bariatric surgery," noted the American Association of Clinical Endocrinology in its 2023 obesity management algorithm.

Strategies to Lower Your Zepbound Cost in Colorado

Seven concrete steps Colorado patients can take to reduce what they pay.

Step 1: Check insurance formulary status first. Before anything else, call your insurer with the NDC number and ask for formulary tier, prior authorization requirements, and any step-therapy mandates. Getting a denial on paper is actually useful because it opens the appeals pathway.

Step 2: Apply for the Eli Lilly savings card. If you have commercial insurance, this is the fastest path to $25 per month. Enrollment takes minutes online.

Step 3: Use Lilly's cash-pay program if uninsured. The $550 per month cash-pay price is available to patients without any insurance coverage for the drug.

Step 4: Appeal insurance denials. Colorado law requires insurers to provide an external review process for denied claims. Peer-to-peer reviews between your prescriber and the insurance medical director overturn a meaningful percentage of initial denials.

Step 5: Ask about patient assistance programs. Lilly's Zepbound Patient Assistance Program provides the medication at no cost to patients who meet income eligibility criteria (generally at or below 400% of the federal poverty level).

Step 6: Compare pharmacy pricing. Use GoodRx, RxSaver, or Cost Plus Drugs to compare cash-pay pricing across Colorado pharmacies. Costco pharmacies (which do not require a membership for pharmacy services in Colorado) sometimes offer lower cash prices.

Step 7: Discuss compounded tirzepatide with your provider. If brand Zepbound is financially inaccessible and you understand the trade-offs, a licensed 503A compounding pharmacy in Colorado can fill a prescription for approximately $249 per month.

What to Expect When Starting Zepbound in Colorado

The clinical onboarding process follows a standard dose-escalation schedule regardless of where you fill the prescription. You begin at 2.5 mg once weekly for the first four weeks. This starting dose is for tolerability, not therapeutic effect. Your prescriber increases the dose to 5 mg at week five, then makes subsequent 2.5 mg increases at minimum four-week intervals based on tolerability and response, up to a maximum of 15 mg weekly.

Common side effects during titration include nausea (reported in 24% of participants in SURMOUNT-1 at the 15 mg dose), diarrhea, constipation, and injection-site reactions. Most gastrointestinal side effects are mild to moderate and diminish after the first 8 to 12 weeks of treatment. Eating smaller meals, staying hydrated, and avoiding high-fat foods during dose escalation can reduce nausea severity.

Lab monitoring is not strictly mandated by the FDA label but most Colorado prescribers order baseline and periodic labs including a comprehensive metabolic panel, lipid panel, and HbA1c. Patients with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome should not use tirzepatide due to the boxed warning regarding thyroid C-cell tumors observed in rodent studies.

The first fill is the least expensive month if you have insurance coverage with the savings card: 2.5 mg pens cost the same as 15 mg pens, so there is no financial advantage to staying on a lower dose longer than clinically indicated.